Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page
- Check4 days agoChange DetectedAdded a Locations section listing Pennsylvania and Texas as study sites, replacing the former Pennsylvania Locations and Texas Locations entries.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page now displays a new revision label, v3.3.2, replacing v3.3.1, indicating a minor update to the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedPublications note wording updated to indicate items are automatically filled from PubMed. Revision tag updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check41 days agoChange DetectedNotice about a lapse in government funding and related operating-status information was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check55 days agoChange DetectedNo significant content changes detected between the screenshots; the page content remains the same aside from minor UI updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check83 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference4%

Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.